BOULDER, Colo. (AP) _ Clovis Oncology Inc. (CLVS) on Wednesday reported a loss of $66.3 million in its first quarter.
The Boulder, Colorado-based company said it had a loss of 64 cents per share.
The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 72 cents per share.
The biopharmaceutical company posted revenue of $38.1 million in the period, which did not meet Street forecasts. Four analysts surveyed by Zacks expected $44.8 million.
Clovis shares have increased 15% since the beginning of the year. The stock has declined 32% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CLVS at https://www.zacks.com/ap/CLVS